Observational Study of Pacing Therapy for Atrial Tachycardia in Congenital Heart Disease

This study is looking at how well Medtronic pacing devices work to manage atrial tachycardia (a fast, irregular heartbeat) in people with congenital heart disease (heart problems present at birth). Researchers will review existing medical records to see if the pacing therapy, delivered by an implanted device, changes the amount of atrial arrhythmia (irregular heartbeats) over at least five years. You could be eligible if you have structural congenital heart disease, an atrial arrhythmia, and an implanted Medtronic device with its pacing therapy turned on. The study is currently recruiting participants by reviewing existing patient data, aiming for 250 to 300 individuals.

Study design
This is an observational study, meaning researchers will review existing medical records rather than conducting new interventions. The study aims to include 250 to 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' medical records will be reviewed to measure changes in atrial arrhythmia over a minimum of five years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03209583

ATrial Tachycardia PAcing Therapy in Congenital Heart

Recruiting
Not specifiedAll AgesObservational
Ian Law
~300 participants
Updated 2026-03-13 on ClinicalTrials.gov
What's tested:Medtronic

At a glance

Recruiting sites
9 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To measure any change in IART burden before and after ATD implantation.
Measured over 5 years at minimum
Atrial Arrhythmia
Atrial Tachycardia
Congenital Heart Disease
Pacemaker Re-Entrant Tachycardia

NCT03209583

Where you'd take part

This study runs at 15 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baylor College of Medicine

    Houston, Texasstudy coordinator listed

    Recruiting

  • University of Iowa Children's Hospital

    Iowa City, Iowastudy coordinator listed

    Recruiting

  • Children's Hospital of Michigan

    Detroit, Michiganno site contact published

    Recruiting

  • Children's Hospital of Orange County (CHOC)

    Orange, Californiano site contact published

    Recruiting

  • Indiana University Health

    Indianapolis, Indianano site contact published

    Not yet recruiting

  • Mayo Clinic

    Rochester, Minnesotano site contact published

    Not yet recruiting

  • Memorial Healthcare System

    Hollywood, Floridano site contact published

    Not yet recruiting

  • Norton Healthcare

    Louisville, Kentuckyno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

must have structural CHD, an atrial arrhythmia and an ATD implanted. ATP must be turned on.

Exclusion

Other arrhythmias substrates such as Long QT (LQT), hypertrophic Cardiomyopathy (HCM), Catecholaminergic polymorphic ventricular tachycardia (CPVT), Arrhythmogenic Right Ventricular Cardiomyopathy.(ARVC), Brugada \& patients who undergo transplant, surgical maze, or ablation within 5 years of ATD implantation.
  • To measure any change in IART burden before and after ATD implantation.5 years at minimum

    The comparison will be how many times a cardioversion was needed and or how many times the device was able to or wasn't able to pace the heart out of the fast rate which could otherwise have been treated with a cardioversion. Data will be collected for a maximum of 5 years prior to implantation of an ATD and compared to a maximum of 5 years post implantation.